Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263106 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2216684 and Theophylline in Healthy Subjects
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01263106 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 21 participants.
The verdict
NCT01263106, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy participants, this study will also assess heart rate when coadministered with theophylline.
Interventions
- DRUG Theophylline
- DRUG LY2216684
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01263106
The ClinicalTrials.gov registry entry for NCT01263106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Theophylline is the first listed.
NCT01263106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01263106 about?
NCT01263106 is a clinical study titled "A Study of LY2216684 and Theophylline in Healthy Subjects". The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy participants, this study wil...
What is the current status of trial NCT01263106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-12. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01263106?
The interventions under investigation include: Theophylline (DRUG), LY2216684 (DRUG).
Who is sponsoring clinical trial NCT01263106?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.